PMC Articles for PubChem BioAssay (Select 1345540) - PMC

Result Filters

Links from PubChem BioAssay

Items: 4

Select item 111591461.

E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

Takayuki Nakagawa, Osamu Tohyama, Atsumi Yamaguchi, Tomohiro Matsushima, Keiko Takahashi, Setsuo Funasaka, Shuji Shirotori, Makoto Asada, Hiroshi Obaishi

Cancer Sci. 2010 Jan; 101(1): 210–215. Published online 2009 Sep 2. doi: 10.1111/j.1349-7006.2009.01343.x

PMCID:: PMC11159146

Abstract Article PDF–423K

Select item 48261922.

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

Parag P. Patwardhan, Kathryn S. Ivy, Elgilda Musi, Elisa de Stanchina, Gary K. Schwartz

Oncotarget. 2016 Jan 26; 7(4): 4093–4109. Published online 2015 Dec 10. doi: 10.18632/oncotarget.6547

PMCID:: PMC4826192

Abstract Article PDF–6.5M

Select item 37171593.

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose Ajamie, Sean G. Buchanan, Jeremy R. Graff, Steven A. Heidler, Yu-Hua Hui, Karen L. Huss, Bruce W. Konicek, Jason R. Manro, Chuan Shih, Julie A. Stewart, Trent R. Stewart, Stephanie L. Stout, Mark T. Uhlik, Suzane L. Um, Yong Wang, Wenjuan Wu, Lei Yan, Wei J. Yang, Boyu Zhong, Richard A. Walgren

Invest New Drugs. 2013; 31(4): 833–844. Published online 2012 Dec 29. doi: 10.1007/s10637-012-9912-9